Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02)

Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Pfeifer, Heike, Cayuela, Jean-Michel, Spiekermann, Karsten, Beck, Joachim, Jung, Wolfram E., Viardot, Andreas, Kerstin, Schaefer-Eckart, Reichle, Albrecht, Maury, Sebastien, Schmitz, Norbert, Heidenreich, Daniela, Panse, Jens, Junghanss, Christian, Raffoux, Emmanuel, Suarez, Felipe, Guillerm, Gaeelle, Alexis, Magda, Lissandre, Severine, Huguet, Francoise, Isnard, Francoise, Lepretre, Stephane, Escoffre-Barbe, Martine, Ribera, Josep-Maria, Goekbuget, Nicola, Dombret, Herve, Hoelzer, Dieter and Rousselot, Philippe 2014. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood 124 (21) , p. 798.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	02 Nov 2022 09:55
URI:	https://orca.cardiff.ac.uk/id/eprint/96789

Actions (repository staff only)

Edit Item

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)